Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

HCL Anticipates Increasing Demand For Locums As NHS Funding Is Squeezed, UK
HCL, the UK"s largest health and social care recruiter, said today that it anticipates increasing demand for its temporary and locum staff as the NHS seeks to increase efficiencies in healthcare provision.
generic viagra online
BCBSGA Announces Decision To Cover H1N1 Vaccine Administration
Blue Cross and Blue Shield of Georgia (BCBSGA) announced that it will offer coverage for the administration of the H1N1 (swine flu) vaccine when it becomes commercially available to the general public. The vaccine administration will be covered for members whose benefit plans provide coverage for vaccines.
News of the day
Increased Risk Of Emphysema Following Childhood Exposure To Tobacco Smoke
Chronic exposure to tobacco smoke in childhood may contribute to early emphysema later in life, according to new research. Environmental tobacco smoke (ETS) is known to be associated with a variety of serious health problems, but it had not previously been associated with the development of emphysema over the life course. The data was presented on Tuesday, May 19, at the 105th International Conference of the American Thoracic Society in San Diego.
Medical Devices

Tapentadol Tablets For Moderate To Scute Pain In Over 18s Now Available For Use In The United States

German pain expert company GrÃønenthal GmbH announces that the new centrally acting analgesic tapentadol is now available in the United States. The drug is indicated for the relief of moderate to severe acute pain in patients 18 years of age and older. Approval was given by the US Food and Drug Administration (FDA) in November 2008 for tapentadol (NUCYNTATM) tablets. With the cooperation of GrÃønenthal and its marketing partner Ortho-McNeil-Janssen Pharmaceuticals, Inc., the medication can now be prescribed by physicians and other appropriate health care professionals in the United States. "This first launch of tapentadol which has been discovered by GrÃønenthal and co-developed with Johnson & Johnson Pharmaceutical Research & Development, L.L.C, is an important step in our endeavour to further improve pain management worldwide", said Dr. Alberto Grua, Head of Palexia Global Division, Global Commercial Operations of GrÃønenthal. "The US patients are the first to benefit from tapentadol which shows comparable efficacy to strong classical opioids and offers a favourable tolerability profile." More than 25 million Americans experience acute pain each year as a result of injuries or surgery1, and acute pain is the most common reason people seek medical attention.2 The FDA approval of tapentadol was based on data from clinical studies involving more than 2.100 patients with acute pain. The studies found that tapentadol provided significant relief of moderate to severe acute pain compared to placebo. In Europe, GrÃønenthal has submitted the Marketing Authorisation Application for two tablet formulations (tapentadol and tapentadol prolonged-release tablets) to several European authorities in April 2009. GrÃønenthal is seeking a European indication for the relief of severe acute pain and the management of severe chronic pain requiring centrally acting analgesic therapy in adults 18 years of age and older. Tapentadol is the first new substance in its class for more than 25 years. About Tapentadol Tapentadol has been under development for severe chronic pain. In the United States, tapentadol was approved by the Food and Drug Administration on November 20, 2008 for the relief of moderate to severe acute pain in patients 18 years of age or older. On April 30th, 2009 GrÃønenthal has submitted the Marketing Authorisation Application for tapentadol and tapentadol prolonged release to several European authorities. GrÃønenthal is also preparing the submission of tapentadol to regulatory authorities in Switzerland, Australia, New Zealand, Singapore, Russia, Ukraine, Saudi Arabia, Mexico, and Venezuela in 2009. Other countries will follow later. Two Mechanisms of Action Tapentadol has a unique profile with two mechanisms of action, combining mu-opioid receptor agonism and noradrenaline reuptake inhibition properties in a single molecule. Preclinical studies suggest that both mechanisms contribute to the analgesic effects of tapentadol. Îúu-receptor agonists are drugs which act at various levels in the pain pathway, by inhibiting the transmission of the pain signal, the emotional aspect of pain and pain realisation. In addition, the analgesic effect of tapentadol, can be explained by the descending inhibition arising from the noradrenaline reuptake inhibition, a recognized analgesic mechanism. Tapentadol Partnership GrÃønenthal discovered tapentadol. GrÃønenthal and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) have conducted the Phase IIb and III development programs for tapentadol for acute and chronic pain conditions. GrÃønenthal licensed exclusive rights to tapentadol to Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), for the United States, Canada and Japan. PriCara®, a division of Ortho-McNeil-Janssen Pharmaceutical, Inc. will market tapentadol in the United States. GrÃønenthal holds the rights in Europe and other countries worldwide. References 1. National Pain Survey (1999). The American Pain Foundation. Conducted for Ortho-McNeil Pharmaceutical 2. Coda BA, Bonica JJ. General considerations of acute pain. In: Loeser JD, Butler SH, Chapman CR, et al, eds. Bonica"s Management of Pain. 3rd ed. Baltimore, MD: Lippincott Williams & Wilkins; 2001:222-240. GrÃønenthal


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009